13F-HR filed by Stonepine Capital Management, LLC
Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2023-03-31, filed 2023-05-12, with 22 holding rows worth $298,170,913.
- Accession
- 0000935836-23-000397
- Filer
- CIK 1440771
- Filed
- 2023-05-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2023
A holdings report, 22 entries on the cover page, a total value of $298,170,913 stated on the cover page (in dollars after the unit check, H1), rows summing to $298,170,913 with VALUE read as dollars as filed, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AMRYT PHARMA LTD - SPNR ADR | 03217L106 | COMMON EQUITY | 6,278,085 | $91,534,479 | dollars as filed | |
| LAKEFRONT BIOTHERAPEUTICS NV | 36315X101 | SPON ADR | 782,289 | $30,227,647 | dollars as filed | |
| CTI BIOPHARMA CORP | 12648L601 | COM | 6,535,674 | $27,449,831 | dollars as filed | |
| ADMA BIOLOGICS INC | 000899104 | COM | 7,661,690 | $25,360,194 | dollars as filed | |
| QUIDELORTHO CORP COM | 219798105 | Stock | 279,081 | $24,863,326 | dollars as filed | |
| XERIS BIOPHARMA HOLDINGS INC | 98422E103 | COM | 8,640,205 | $14,083,534 | dollars as filed | |
| MAXCYTE INC | 57777K106 | COM | 2,707,090 | $13,400,096 | dollars as filed | |
| THIRD HARMONIC BIO INC | 88427A107 | COM | 3,131,995 | $12,903,819 | dollars as filed | |
| ATYR PHARMA INC | 002120202 | COM NEW | 4,825,722 | $10,134,016 | dollars as filed | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 318,096 | $6,715,007 | dollars as filed | |
| CASTLE BIOSCIENCES INC | 14843C105 | COMMON STOCK | 292,866 | $6,653,916 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 701,535 | $6,482,183 | dollars as filed | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 3,087,649 | $5,928,286 | dollars as filed | |
| EVOLUS INC | 30052C107 | COM | 578,795 | $4,896,606 | dollars as filed | |
| DYNAVAX TECHNOLOGIES CORP | 268158201 | COM NEW | 416,519 | $4,086,051 | dollars as filed | |
| APOLLO ENDOSURGERY INC | 03767D108 | COM | 370,000 | $3,670,400 | dollars as filed | |
| TRAVERE THERAPEUTICS INC | 89422G107 | COM | 132,005 | $2,968,792 | dollars as filed | |
| EXAGEN INC | 30068X103 | COM | 1,037,074 | $2,520,090 | dollars as filed | |
| ATEA PHARMACEUTICALS INC | 04683R106 | COMMON STOCK | 684,508 | $2,293,102 | dollars as filed | |
| SCYNEXIS INC | 811292200 | COM NEW | 450,000 | $1,350,000 | dollars as filed | |
| CONFORMIS INC COM NEW | 20717E200 | Stock | 402,651 | $648,268 | dollars as filed | |
| CIDARA THERAPEUTICS INC COM NEW | 171757107 | Stock | 1,000 | $1,270 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000935836-23-000397 | this filing | 2023-05-12 | acceptance time not in the bulk data set |